治疗 COVID-19 药物与癌症治疗药物相互作用的注意事项。
Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments.
机构信息
Department of Radiation Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
出版信息
Crit Rev Oncol Hematol. 2020 Jul;151:102982. doi: 10.1016/j.critrevonc.2020.102982. Epub 2020 May 12.
Abstract
SARS-CoV2 infection is an emerging issue worldwide. Cancer patient are at increased risk of infection compared to general population. On the other hand, these patients are at major risk of drug interactions caused by renal and hepatic impairment background. Because of the long-term use of chemotherapy drugs, drug interactions are important in these patients especially with SARS-CoV2 treatments now. This paper is review of reported drug interactions of current treatments for COVID-19 and anticancer agents.
摘要
SARS-CoV2 感染是全球范围内的一个新出现的问题。与一般人群相比，癌症患者感染的风险更高。另一方面，这些患者由于肾功能和肝功能受损，药物相互作用的风险很大。由于长期使用化疗药物，药物相互作用在这些患者中很重要，特别是在目前针对 SARS-CoV2 的治疗中。本文综述了目前 COVID-19 治疗药物和抗癌药物的药物相互作用报道。
相似文献
1
Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments.治疗 COVID-19 药物与癌症治疗药物相互作用的注意事项。
Crit Rev Oncol Hematol. 2020 Jul;151:102982. doi: 10.1016/j.critrevonc.2020.102982. Epub 2020 May 12.
2
Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?癌症患者的抗癌药物和 COVID-19 抗病毒治疗：我们可以安全使用哪些药物？
Eur J Cancer. 2020 Sep;136:1-3. doi: 10.1016/j.ejca.2020.05.027. Epub 2020 Jun 10.
3
Management of COVID-19 in people with epilepsy: drug considerations.COVID-19 患者的癫痫管理：药物相关问题。
Neurol Sci. 2020 Aug;41(8):2005-2011. doi: 10.1007/s10072-020-04549-5. Epub 2020 Jun 27.
4
Considerations for Statin Therapy in Patients with COVID-19.新型冠状病毒肺炎患者他汀类药物治疗的考量因素
Pharmacotherapy. 2020 May;40(5):484-486. doi: 10.1002/phar.2397. Epub 2020 May 4.
5
COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature.COVID-19 疗法和抗癌药物：近期文献的系统评价。
Crit Rev Oncol Hematol. 2020 Aug;152:102991. doi: 10.1016/j.critrevonc.2020.102991. Epub 2020 May 21.
6
Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions.移植受者感染 SARS-CoV-2 的药物治疗：治疗药物监测和药物相互作用的考虑因素。
Ther Drug Monit. 2020 Jun;42(3):360-368. doi: 10.1097/FTD.0000000000000761.
7
[Drug interaction monitoring of lopinavir/ritonavir in COVID-19 patients with cancer].[新冠肺炎合并癌症患者中洛匹那韦/利托那韦的药物相互作用监测]
Zhonghua Nei Ke Za Zhi. 2020 May 1;59(5):400-404. doi: 10.3760/cma.j.cn112138-20200219-00097.
8
Interactions of recommended COVID-19 drugs with commonly used psychotropics.推荐的新冠病毒治疗药物与常用精神药物的相互作用。
Asian J Psychiatr. 2020 Aug;52:102173. doi: 10.1016/j.ajp.2020.102173. Epub 2020 May 21.
9
[Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic].[关于法国在新冠疫情期间精神药物及其对精神障碍患者适应性的信息]
Encephale. 2020 Jun;46(3S):S14-S34. doi: 10.1016/j.encep.2020.04.006. Epub 2020 May 4.
10
Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment.探索性新冠肺炎治疗中药物相互作用对QTc的影响因素
Circulation. 2020 Jun 16;141(24):e906-e907. doi: 10.1161/CIRCULATIONAHA.120.047521. Epub 2020 Apr 8.
引用本文的文献
1
Favipiravir-induced bradycardia: A case report.法匹拉韦诱发的心动过缓：一例报告。
Clin Case Rep. 2024 Jun 27;12(7):e9052. doi: 10.1002/ccr3.9052. eCollection 2024 Jul.
2
Favipiravir, an antiviral drug, in combination with tamoxifen exerts synergistic effect in tamoxifen-resistant breast cancer cells via hTERT inhibition.抗病毒药物法匹拉韦与他莫昔芬联合通过抑制端粒酶逆转录酶（hTERT）在他莫昔芬耐药乳腺癌细胞中发挥协同作用。
Sci Rep. 2024 Jan 22;14(1):1844. doi: 10.1038/s41598-024-51977-w.
3
Evaluation of clinical outcomes, laboratory and imaging data of patients with solid tumor infected with COVID-19 infection.对感染新型冠状病毒肺炎的实体瘤患者的临床结局、实验室及影像学数据进行评估。
Int J Biochem Mol Biol. 2022 Dec 15;13(6):77-86. eCollection 2022.
4
Discovery of Novel and Highly Potent Inhibitors of SARS CoV-2 Papain-Like Protease Through Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, Molecular Dynamics Simulations, and Biological Evaluation.通过基于结构的药效团建模、虚拟筛选、分子对接、分子动力学模拟和生物学评估发现新型高效的严重急性呼吸综合征冠状病毒2木瓜样蛋白酶抑制剂
Front Pharmacol. 2022 Feb 21;13:817715. doi: 10.3389/fphar.2022.817715. eCollection 2022.
5
Potential interactions between antineoplastic agents and medicines used to treat Covid-19.抗肿瘤药物与用于治疗 COVID-19 药物的潜在相互作用。
J Oncol Pharm Pract. 2022 Dec;28(8):1737-1748. doi: 10.1177/10781552211040494. Epub 2021 Oct 12.
6
Recommendations for developing clinical care protocols during pandemics: From theory and practice.大流行期间制定临床护理方案的建议：从理论到实践。
Best Pract Res Clin Anaesthesiol. 2021 Oct;35(3):461-475. doi: 10.1016/j.bpa.2021.02.002. Epub 2021 Feb 27.
7
Pain management in COVID-19 pediatric patients-An evidence- based review.新冠病毒感染儿科患者的疼痛管理——一项基于证据的综述
Saudi J Anaesth. 2021 Jan-Mar;15(1):33-39. doi: 10.4103/sja.SJA_635_20. Epub 2021 Jan 5.
8
Science's Response to CoVID-19.科学应对新冠病毒。
ChemMedChem. 2021 Aug 5;16(15):2288-2314. doi: 10.1002/cmdc.202100079. Epub 2021 Jun 22.
9
An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?抗2019冠状病毒病病毒疗法的最新进展：我们取得了多大的进展？
Front Pharmacol. 2021 Mar 8;12:632677. doi: 10.3389/fphar.2021.632677. eCollection 2021.
10
Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies.重新利用的 COVID-19 药物与肺癌药物治疗的潜在药物相互作用。
Arch Med Res. 2021 Apr;52(3):261-269. doi: 10.1016/j.arcmed.2020.11.006. Epub 2020 Nov 17.
本文引用的文献
1
Interleukin-6 in Covid-19: A systematic review and meta-analysis.白细胞介素 6 在新冠病毒感染中的作用：系统评价和荟萃分析。
Rev Med Virol. 2020 Nov;30(6):1-9. doi: 10.1002/rmv.2141. Epub 2020 Aug 26.
2
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.美国食品药品监督管理局批准的药物伊维菌素可抑制 SARS-CoV-2 的体外复制。
Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.
3
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection.法匹拉韦：药代动力学与对 2019 新型冠状病毒感染临床试验的关注。
Clin Pharmacol Ther. 2020 Aug;108(2):242-247. doi: 10.1002/cpt.1844. Epub 2020 Apr 21.
4
Covid-19 - The Search for Effective Therapy.新冠病毒-19：寻找有效疗法
N Engl J Med. 2020 May 7;382(19):1851-1852. doi: 10.1056/NEJMe2005477. Epub 2020 Mar 18.
5
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
6
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.2019 冠状病毒病（COVID-19）疫情的起源、传播和临床治疗——现状更新。
Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0.
7
Discovering drugs to treat coronavirus disease 2019 (COVID-19).发现治疗2019冠状病毒病（COVID-19）的药物。
Drug Discov Ther. 2020;14(1):58-60. doi: 10.5582/ddt.2020.01012.
8
Remdesivir as a possible therapeutic option for the COVID-19.瑞德西韦作为治疗新冠肺炎的一种可能选择。
Travel Med Infect Dis. 2020 Mar-Apr;34:101615. doi: 10.1016/j.tmaid.2020.101615. Epub 2020 Mar 5.
9
Risk of COVID-19 for patients with cancer.癌症患者感染新冠病毒的风险。
Lancet Oncol. 2020 Apr;21(4):e181. doi: 10.1016/S1470-2045(20)30149-2. Epub 2020 Mar 3.
10
The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.抗病毒化合物瑞德西韦能有效抑制中东呼吸综合征冠状病毒的 RNA 依赖性 RNA 聚合酶。
J Biol Chem. 2020 Apr 10;295(15):4773-4779. doi: 10.1074/jbc.AC120.013056. Epub 2020 Feb 24.
Zotero 插件